Obinutuzumab-atezolizumab-lenalidomide for ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Auteur(s) :
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Ghosh, Nilanjan [Auteur]
Lossos, Izidore S. [Auteur]
University of Miami Leonard M. Miller School of Medicine [UMMSM]
Palomba, M. Lia [Auteur]
Memorial Sloane Kettering Cancer Center [New York]
Mehta, Amitkumar [Auteur]
University of Alabama at Birmingham [ Birmingham] [UAB]
Casasnovas, Olivier [Auteur]
Service d'Hématologie Clinique (CHU de Dijon)
Stevens, Don [Auteur]
Katakam, Sudhakar [Auteur]
F. Hoffmann-La Roche [Basel]
Knapp, Andrea [Auteur]
F. Hoffmann-La Roche [Basel]
Nielsen, Tina [Auteur]
F. Hoffmann-La Roche [Basel]
Mccord, Ron [Auteur]
Genentech, Inc. [San Francisco]
Salles, Gilles [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Ghosh, Nilanjan [Auteur]
Lossos, Izidore S. [Auteur]
University of Miami Leonard M. Miller School of Medicine [UMMSM]
Palomba, M. Lia [Auteur]
Memorial Sloane Kettering Cancer Center [New York]
Mehta, Amitkumar [Auteur]
University of Alabama at Birmingham [ Birmingham] [UAB]
Casasnovas, Olivier [Auteur]
Service d'Hématologie Clinique (CHU de Dijon)
Stevens, Don [Auteur]
Katakam, Sudhakar [Auteur]
F. Hoffmann-La Roche [Basel]
Knapp, Andrea [Auteur]
F. Hoffmann-La Roche [Basel]
Nielsen, Tina [Auteur]
F. Hoffmann-La Roche [Basel]
Mccord, Ron [Auteur]
Genentech, Inc. [San Francisco]
Salles, Gilles [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Titre de la revue :
Blood Cancer Journal
Nom court de la revue :
Blood Cancer J
Numéro :
11
Pagination :
147
Éditeur :
Nature Publishing Group
Date de publication :
2021-08-20
ISSN :
2044-5385
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). ...
Lire la suite >We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). An initial 3 + 3 dose‐escalation phase to define the recommended phase II dose of lenalidomide was followed by an expansion phase with G-atezo-len induction and maintenance. At final analysis, 38 patients (lenalidomide 15 mg, n = 4; 20 mg, n = 34) had completed the trial. Complete response rate for the efficacy population (lenalidomide 20 mg, n = 32) at end-of-induction was 71.9% (66.7% in double‐refractory patients [refractory to rituximab and alkylator] [n = 12]; 50.0% in patients with progressive disease within 24 months of first-line therapy [n = 12]). The 36-month progression-free survival rate was 68.4%. All treated patients had ≥1 adverse event (AE; grade 3–5 AE, 32 patients [84%]; serious AE, 18 patients [47%]; AEs leading to discontinuation of any study drug, 11 patients [29%]). There were 2 fatal AEs (1 merkel carcinoma, 1 sarcomatoid carcinoma; both unrelated to any study drug). The G‐atezo-len regimen is effective and tolerable in patients with R/R FL. AEs were consistent with the known safety profile of the individual drugs.Lire moins >
Lire la suite >We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). An initial 3 + 3 dose‐escalation phase to define the recommended phase II dose of lenalidomide was followed by an expansion phase with G-atezo-len induction and maintenance. At final analysis, 38 patients (lenalidomide 15 mg, n = 4; 20 mg, n = 34) had completed the trial. Complete response rate for the efficacy population (lenalidomide 20 mg, n = 32) at end-of-induction was 71.9% (66.7% in double‐refractory patients [refractory to rituximab and alkylator] [n = 12]; 50.0% in patients with progressive disease within 24 months of first-line therapy [n = 12]). The 36-month progression-free survival rate was 68.4%. All treated patients had ≥1 adverse event (AE; grade 3–5 AE, 32 patients [84%]; serious AE, 18 patients [47%]; AEs leading to discontinuation of any study drug, 11 patients [29%]). There were 2 fatal AEs (1 merkel carcinoma, 1 sarcomatoid carcinoma; both unrelated to any study drug). The G‐atezo-len regimen is effective and tolerable in patients with R/R FL. AEs were consistent with the known safety profile of the individual drugs.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Équipe(s) de recherche :
Modélisation biopharmaceutique et pharmacocinétique
Date de dépôt :
2023-05-25T03:01:39Z
2023-10-03T14:32:27Z
2023-10-03T14:32:27Z
Fichiers
- Obinutuzumab-atezolizumab-lenalidomide for the .pdf
- Version éditeur
- Accès libre
- Accéder au document